Advertisement

Topics

Hagens Berman Reminds Toshiba Corporation (OTC: TOSYY, TOSBF) Investors of August 3, 2015 Deadline in Class Action Involving a Now Admitted $1.22 Billion Accounting Scandal

20:00 EDT 20 Jul 2015 | Globe Newswire

SAN FRANCISCO, July 21, 2015 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, reminds investors of the August 3, 2015 lead plaintiff deadline in the securities fraud class action lawsuit filed against Toshiba Corporation (OTC:TOSYY) (OTC:TOSBF) (“Toshiba” or “the Company”) as a result of a now admitted accounting cover-up that began in 2008.

If you have losses in excess of $100,000.00 in TOSYY or TOSBF securities during the Class Period, or for purchases after July 22, 2010, contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000, emailing TOSYY@hbsslaw.com or visiting http://hb-securities.com/investigations/TOSYY.

The lawsuit, pending in U.S. District Court for the Central District of California, is filed on behalf of investors who purchased Toshiba securities between May 8, 2012 and May 7, 2015, inclusive, (the “Class Period”) and seeks damages caused by the need to restate profits. The deadline to move for the position of lead plaintiff in the case is August 3, 2015.

On April 3, 2015 Toshiba issued a press release announcing that they were establishing a committee to investigate the accounting of certain infrastructure projects.  On this adverse news, shares of TOSYY fell $1.23 per share, or over 4%, from its previous closing price to close at $24.56 per share on April 6, 2015, and shares of TOSBF fell $0.16 per share or over 3% from its previous closing price to close at $4.13 per share on April 6, 2015.

Toshiba announced on May 8, 2015 that another, independent investigation committee would be investigating whether certain construction projects were understating costs. Following this announcement, shares of TOSYY fell $5.75 per share, or over 23%, over the next two days to close at $18.33 per share on May 11, 2015 and shares of TOSBF fell $0.88 per share or over 22% over the next two days to close at $3.09 per share on May 11, 2015.

Today, July 21, 2015, Toshiba’s CEO Hisao Tanaka and eight other executives resigned, and acknowledged a cover up that began in 2008.  Those resigning took responsibility for doctored books that inflated profits by $1.2 billion over several years.

If you were negatively impacted over $100,000 by your investment in Toshiba securities between May 8, 2012 and May 7, 2015, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.

Whistleblowers: Persons with non-public information regarding Toshiba should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at (510) 725-3000 or email TOSYY@hbsslaw.com.

About Hagens Berman
Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm headquartered in Seattle, Washington with offices in nine cities. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. Read the firm’s Securities Newsletter at http://www.hb-securities.com/newsletter. The firm’s blog is located at www.meaningfuldisclosure.com.For the latest news from Hagens Berman, visit http://www.hbsslaw.com/newsroom or follow us on Twitter at @hagensberman.

Contact:
Reed Kathrein, (510) 725-3000

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Hagens Berman Reminds Toshiba Corporation (OTC: TOSYY, TOSBF) Investors of August 3, 2015 Deadline in Class Action Involving a Now Admitted $1.22 Billion Accounting Scandal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...